fbpx

CoQ10 to Improve Ejection Fraction in Congestive Heart Failure

Share Button

“Pooled analyses of available randomized controlled trials suggest that CoQ₁₀ may improve the Ejection Fraction in patients with congestive heart failure”

I have chronic atrial fibrillation aka A-Fib. A-Fib is a pretty common side-effect of high dose chemotherapy. I’ve read that I can live a long and happy life (EveryDay Health) if I take care of my heart and avoid congestive heart failure…

The study linked and excerpted below states that Coq10 supplementation (100mg daily) improves ejection fraction. Not to get too technical but since my heart rhythm is way off, blood flow both in and out is also way off. Coq10 keeps the heart muscle strong keeping the ejection fraction up.

Coq10 supplementation is an easy, cost-effective therapy.

  • Coq10 is evidence-based, well-researched therapy for its many health benefits-
  • Cost-effective at .15 per 100mg  (lowest cost of ConsumerLab’s evaluation of CoQ10 with bioavailability enhancer)-

I am a cancer survivor and cancer coach. For more information about short, long-term and late stage side effects of aggressive chemotherapy, scroll down the page, post a question or comment and I will reply ASAP.

Thank you,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancr

Recommended Reading:


Effect of coenzyme Q₁₀ supplementation on heart failure: a meta-analysis.

“The objective of this meta-analysis was to evaluate the impact of CoQ₁₀ supplementation on the ejection fraction (EF) and New York Heart Association (NYHA) functional classification in patients with CHF…

Supplementation with CoQ₁₀ resulted in a pooled mean net change of 3.67%  in the EF… Subgroup analyses showed significant improvement in EF for crossover trials, trials with treatment duration ≤12 wk in length, studies published before 1994, and studies with a dose ≤100 mg CoQ₁₀/d and in patients with less severe CHF. These subgroup analyses should be interpreted cautiously because of the small number of studies and patients included in each subgroup…

CONCLUSIONS: Pooled analyses of available randomized controlled trials suggest that CoQ₁₀ may improve the EF in patients with CHF. Additional well-designed studies that include more diverse populations are needed.”

Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem

“The burden of cardiovascular and metabolic diseases is increasing with every year. Although the management of these conditions has improved greatly over the years, it is still far from perfect. With all of this in mind, there is a need for new methods of prophylaxis and treatment.

Coenzyme Q10 (CoQ10) is an essential compound of the human body. There is growing evidence that COQ10 is tightly linked to cardiometabolic disorders. Its supplementation can be useful in a variety of chronic and acute disorders. This review analyses the role of COQ10 in hypertension, ischemic heart disease, myocardial infarction, heart failure, viral myocarditis, cardiomyopathies, cardiac toxicity, dyslipidemia, obesity, type 2 diabetes mellitus, metabolic syndrome, cardiac procedures and resuscitation…

CoQ10 AND ARRHYTHMIAS

The prevalence of the Atrial Fibrillation (AF) and HF are growing worldwide year by year []. Atrial fibrillation can be called a typical atrial arrhythmia in patients diagnosed with HF. It is associated with an increase in morbidity and mortality [, ].

CoQ10 plays an important role in oxydative phosphorilation, producing ATP and this bioenergetic function is essential for proper heart functioning []. Besides that, it has the property to scavenge ROS and antioxidant function []…

CARDIOMYOPATHY

Cardiomyopathy is a debilitating condition, which is associated with a high mortality and poor quality of life. There is extensive evidence from in vitro and animal studies that it is linked to increased oxidative stress [].

Mice models of diabetic cardiomyopathy demonstrate that COQ10 decreases diabetes-induced left ventricular diastolic dysfunction; cardiomyocyte hypertrophy, fibrosis and apoptosis; expression of the atrial natriuretic peptide, connective tissue growth factor, pro-inflammatory mediators, and β-myosin heavy chain [, ]…

CONCLUSION- There are many controversial data on the supplementation of COQ10 in different conditions. The reported dosage of COQ10 differs in a wide range 100-300 mg for CV diseases. Limited data on the amount of COQ10 absorbed in the gastrointestinal tract and its amount in the circulating blood were observed.

Rat model demonstrates significant impact at a higher dose when the plasma concentration is increased by more than 80%. Future studies should be aimed at assessment of higher dosage of COQ10 administration as well as evaluation of its pharmacokinetics and pharmacodynamics.

Overall, there seems to be a beneficial role of COQ10 co-administration as a supplemental therapy in different cardiac and metabolic conditions. The changes in the antioxidant systems in these conditions support the idea that COQ10 may improve outcome, quality of life and decrease morbidity and mortality. Nevertheless, the findings of some studies are based on preclinical or clinical studies with surrogate endpoints. This subject should be addressed in the future. Finally, more randomized trials should be performed to assess the impact of COQ10 supplementation on survival.”

Efficacy of Coenzyme Q10 for Improved Tolerability of Cancer Treatments: A Systematic Review

Purpose-The aim of this systematic review was to summarize and evaluate the evidence available for oral supplementation with coenzyme Q10 (CoQ10) to improve the tolerability of cancer treatments

Results-Six studies were included in the review, including three randomized clinical trials and three nonrandomized clinical trials. Patients in five of six studies received anthracyclines. The results suggested that CoQ10 provides some protection against cardiotoxicity or liver toxicity during cancer treatment. However, because of inadequate reporting and analysis, as well as questionable validity of outcome measures, the results are not conclusive.

Conclusion- Suggestions that CoQ10 might reduce the toxicity of cancer treatments have not been tested by rigorous trials. Further investigations are necessary to determine whether CoQ10 can improve the tolerability of cancer treatments


Leave a Comment:

3 comments
Add Your Reply